Clinical Trial to Evaluate the Efficacy and Safety of CKD-390 Tablet

PHASE3UnknownINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

November 30, 2017

Study Completion Date

March 31, 2018

Conditions
Chronic Hepatitis B
Interventions
DRUG

CKD-390

CKD-390 1 Tablet (48 weeks)

DRUG

viread

viread1 Tablet (24 weeks), CKD-390 1 Tablet (from 24 weeks to 48 weeks)

Trial Locations (20)

Unknown

NOT_YET_RECRUITING

Korea University Ansan Hospital, Ansan

NOT_YET_RECRUITING

Bundang Cha Medical Center, Bundang

RECRUITING

Hanyang University Guri Hospital, Guri-si

RECRUITING

Inje University Ilsan Paik Hospital, Ilsan

ACTIVE_NOT_RECRUITING

Gachon University of Medicine and Science Gil Medical Center, Incheon

ACTIVE_NOT_RECRUITING

Ajou University Hospital, Suwon

ACTIVE_NOT_RECRUITING

Busan National University Hospital, Busan

ACTIVE_NOT_RECRUITING

Keimyung University Dongsan Medical Center, Daegu

NOT_YET_RECRUITING

Yeungnam University Medical Center, Daegu

NOT_YET_RECRUITING

Chungnam National University Hospital, Daejeon

NOT_YET_RECRUITING

Jeju National University Hospital, Jeju City

ACTIVE_NOT_RECRUITING

Chungang University Hospital, Seoul

ACTIVE_NOT_RECRUITING

Hanyang University Hospital, Seoul

NOT_YET_RECRUITING

Kangnam Severance Hospital, Seoul

NOT_YET_RECRUITING

Korea University Guro Hosptial, Seoul

ACTIVE_NOT_RECRUITING

Samsung Medical Center, Seoul

ACTIVE_NOT_RECRUITING

Seoul Asan Medical Center, Seoul

ACTIVE_NOT_RECRUITING

Seoul National University Hospital, Seoul

ACTIVE_NOT_RECRUITING

Seoul Saint Mary's Hospital, Seoul

NOT_YET_RECRUITING

Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY

NCT02805738 - Clinical Trial to Evaluate the Efficacy and Safety of CKD-390 Tablet | Biotech Hunter | Biotech Hunter